Loading…
Loading…
Amgen and Gilead pay forward dividend yields above 2%. Gilead has a lower dividend payout ratio, but Amgen is generating stronger sales growth.
Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
Amgen NASDAQ: AMGN presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to durvalumab maintenance treatment, improved survival outcomes for patients with extensive-stage small-cell lung cancer whose disease had not progressed after initial chemoimmunotherapy.
Amgen focuses on high-growth areas including oncology, inflammation, and rare diseases to drive its clinical pipeline. Johnson & Johnson offers a diversified business model split between innovative medicine and global medical technology.
IMDELLTRAÂ IN COMBINATION WITH IMFINZIÂ REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPR NewswireTHOUSAND
A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. Full results from a late-stage trial show that adding Amgen's Imdelltra to AstraZeneca's Imfinzi drug slashed the risk of death by 58% in patients with extensive-stage small cell lung cancer.
Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine Longer DeLLphi-303 Follow-Up Data Showed Median Overall Survival Exceeded 37 Months in First-Line Maintenance with IMDELLTRA and Either IMFINZI or TECENTRIQ® THOUSAND OAKS, Calif., Oct. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI® (durvalumab) reduced the risk of death by 58% as a first-line maintenance treatment for extensive stage small cell lung cancer (ES-SCLC) (hazard ratio [HR]: 0.42; 95% confidence interval [CI]: 0.32, 0.54; P
Amgen (AMGN) closed at $439.26 in the latest trading session, marking a -1.79% move from the prior day.